Results 181 to 190 of about 5,054 (206)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini   +2 more
exaly  

Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease

Journal of Dermatological Treatment, 2021
Natalie Villa, Vivian Y Shi, Jennifer Hsiao   +2 more
exaly  

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

Gastroenterology, 2022
Bruce Sands, Chenglong Han, Silvio Danese   +2 more
exaly  

Guselkumab (Tremfya)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire   +1 more source

Guselkumab (Tremfya) for Ulcerative Colitis

The Medical Letter on Drugs and Therapeutics
The interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of
openaire   +2 more sources

Plaatsbepaling guselkumab = Determining the role of guselkumab

Nederlands Tijdschrift voor Dermatologie en Venereologie, 2020
van Eijsden, Claire, van Doorn, Martijn
openaire   +1 more source

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Expert Review of Clinical Immunology, 2021
Wolf-Henning Boehncke, Michael J Nissen, Nicolò Brembilla   +2 more
exaly  

Etanercept/guselkumab

Reactions Weekly, 2023
openaire   +1 more source

Real‐life experience of guselkumab in patients with psoriasis

Dermatologic Therapy, 2020
Igor Snast
exaly  

Guselkumab in the treatment of moderate-to-severe plaque psoriasis

Immunotherapy, 2020
Luis Puig, Cristina Lopez Sanchez
exaly